A 2-year post-doctoral position, starting on April 1st 2018, is available in the team “Cancer Cell Signaling and Therapeutics” headed by Gilles Favre at the Cancer Research Center of Toulouse (CRCT) in Toulouse. This position is offered in the context of the FRM “labellisation” of the team.


Description

Our research focuses on the mechanisms of acquired resistance to targeted therapy, primarily in lung cancer. A recent mechanism of resistance implies the survival of few tumor cells to treatment, which arrest their proliferation, and acquire over time validated genetic resistance to therapy allowing the tumor to regrowth. The post-doctoral candidate will primarily investigate how non-cycling cells acquire those genetic resistances on the basis of our findings that DNA double-strand breaks, which are highly mutagenic, are produced in noncycling cells when an ongoing transcription complex encounters a topoisomerase I lesion onto chromatin (NAR 2016; MCB 2014; EMBO Rep 2009). This project will include techniques such as ChIP-seq, whole-exome-seq and high content imaging system (Operetta). The selected candidate will perform his (her) research in the highly stimulating environment of the Cancer Research Center of Toulouse (CRCT), which is located in a campus dedicated to cancer bringing together academic research, private companies and a hospital. He (she) will benefit of all the cutting-edge technology platforms of the center.

Applicant profile

We are looking for a highly motivated and enthusiastic applicant with a PhD and a strong background in cellular and molecular biology. Experience in ChIP and genome-wide analyses is preferred but not required. This grant is for funding a first post-doctoral position after a PhD.

Contact

This project will be supervised by Olivier Sordet, a senior scientist in the team. To apply, please reply to olivier.sordet@inserm.fr with a CV including list of publications, a short description of research interests, and 2 recommendation letters.

Additional information

  • Starting date: April 1st 2018
  • Duration: 2 years
  • Gross salary: Inserm’s standard